|
Indication & Dosage |
|
|
Subcutaneous |
PALLIATIVE TREATMENT OF PROSTATIC CARCINOMA |
Adult:
3.6 mg injected into the anterior abdominal wall every 28 days or 10.8 mg every 12 wk. An anti-androgen is given several days before beginning of the treatment and continued for at least 3 wk to prevent disease flare. |
|
Subcutaneous |
PITUITARY DESENSITISATION BEFORE OVULATION INDUCTION WITH GONADOTROPHINS |
Adult:
3.6 mg as a depot inj. Monitor serum-oestradiol concentrations until they decline to levels similar to those in the early follicular phase which takes about 7-21 days. |
|
|
|
Precautions |
Urinary tract obstruction or spinal cord compression (when used for prostate cancer); decreased bone density in women. Contraceptive measures should be taken to protect against pregnancy. Monitor men at risk from tumour flare during the 1st mth of therapy. Safety and efficacy on the usage of the 10.8 mg implant in women is not established. |
|
|
Adverse Drug Reactions |
Vaginal bleeding and dryness, arthralgia, paraesthesias, increase in menstrual bleeding, hot flushes, sexual dysfunction. Headache, emotional lability, depression, insomnia, diaphoresis, dizziness, breast swelling/tenderness, Inj site reactions. Anaphylaxis. |
|
|
|
|